TOLEDO, Ohio & SHANGHAI--(BUSINESS WIRE)--NAMSA, the world’s only Medical Research Organization (MRO), is pleased to announce the opening of its state-of-the-art preclinical medical device research laboratory in Shanghai, China. This opening represents the organization’s third Asian-Pacific location and NAMSA’s growing investment in Chinese-based lab services and commitment to assisting clients in efficiently bringing products to the global marketplace.
The new 80,000 sq. ft. facility will strengthen and expand NAMSA’s MRO® Approach by offering a broad range of laboratory models and analysis tools for preclinical medical device safety and performance evaluations for early-stage R&D development efforts and regulatory submissions.
“NAMSA is excited to add to its global portfolio of services with the introduction of the Shanghai laboratory,” commented Gina Skolmowski, Division President of Lab Services, NAMSA. “Our strong relationship with the China Food and Drug Administration (CFDA), coupled with NAMSA’s proven track record of delivering significant time and cost savings throughout the full medical device lifecycle, will allow our Asian-Pacific clients to further realize efficiencies, including the benefit of closer collaboration.”
NAMSA, the world’s only existing MRO, supports clients throughout all stages of the medical device development process. From concept and feasibility testing to post-market surveillance, services provided by NAMSA accelerate time-to-market and reduce costs related to product research and market introduction. By leveraging nearly 50 years of global knowledge and scientific expertise in balancing speed and quality with proven scientific approaches, NAMSA continues to play a critical, leading role in enhancing patient safety and improving healthcare worldwide.
“The Shanghai laboratory will also allow NAMSA to assist other globally-located clients in their efforts to enter the Chinese marketplace, as well as Asian-Pacific medical device firms wishing to introduce products outside of China. By continuing to offer the highest levels of quality and regulatory compliance available today, NAMSA will continue to be a market leader in world class medical device product development services,” Skolmowski concluded.
The Shanghai laboratory joins NAMSA’s rapidly growing global footprint with existing locations in the US, Germany, UK, France and Japan.
NAMSA’s Shanghai laboratory grand opening activities are planned for November 15-16, 2016, and include an educational conference (MRO Summit), which will highlight regulatory trends and preclinical best practices and strategies. For more information on this event, or to register, please visit the NAMSA website.
About NAMSA
NAMSA is a Medical Research Organization (MRO), accelerating medical device product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA’s MRO® Approach plays an important role in translational research, applying a unique combination of disciplines – consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality – to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements, anywhere in the world.
Follow us on Twitter or LinkedIn for regular updates on NAMSA.
